SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Dec 14, 2016
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Dec. 14, 2016 · CIK: 0001533040 · Accession: 0001193125-16-792798
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214199
Letter
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101 | Marlborough, MA 01752
December 14, 2016
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Joseph McCann
Mary Beth Breslin
Re: RXi Pharmaceuticals Corporation
Registration Statement on Form S-1 (File No. 333-214199)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation (the “Company”) hereby requests that the effective date of the above-captioned registration statement (the “Registration Statement”) be accelerated so that it becomes effective at 4:05 p.m., Eastern Time, on December 15, 2016, or as soon thereafter as practicable.
The Company hereby acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert staff comments and the declaration of the effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 as soon as the Registration Statement has been declared effective.
Very truly yours,
RXi PHARMACEUTICALS CORPORATION
Show Raw Text
CORRESP 1 filename1.htm CORRESP RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 | Marlborough, MA 01752 December 14, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Joseph McCann Mary Beth Breslin Re: RXi Pharmaceuticals Corporation Registration Statement on Form S-1 (File No. 333-214199) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation (the “Company”) hereby requests that the effective date of the above-captioned registration statement (the “Registration Statement”) be accelerated so that it becomes effective at 4:05 p.m., Eastern Time, on December 15, 2016, or as soon thereafter as practicable. The Company hereby acknowledges that: • should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • the Company may not assert staff comments and the declaration of the effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please call Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 as soon as the Registration Statement has been declared effective. Very truly yours, RXi PHARMACEUTICALS CORPORATION By: /s/ Geert Cauwenbergh Name: Geert Cauwenbergh, Dr. Med. Sc. Title: President, Chief Executive Officer and Chief Financial Officer